Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.78 [0.61, 1.00] | | < 1 | | 0% | 1 study (1/-) | 97.6 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.72 [0.57, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | important | - |
DCR | 1.44 [0.95, 2.19] | | > 1 | | 0% | 1 study (1/-) | 95.8 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 4.83 [2.02, 11.57] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 2.89 [1.23, 6.77] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.26 [0.83, 1.90] | | < 1 | | 0% | 1 study (1/-) | 13.9 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 2.11 [1.08, 4.13] | | < 1 | | 0% | 1 study (1/-) | 1.4 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 3.04 [1.32, 6.97] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.66 [1.09, 2.51] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 2.77 [1.36, 5.65] | | < 1 | | 0% | 1 study (1/-) | 0.3 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.24 [0.02, 2.64] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Cough TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.90 [0.14, 58.35] | | < 1 | | 0% | 1 study (1/-) | 24.6 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 0.48 [0.03, 7.71] | | < 1 | | 0% | 1 study (1/-) | 69.7 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.96 [0.09, 10.69] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Dyspepsia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Eczema TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.45 [0.15, 14.03] | | < 1 | | 0% | 1 study (1/-) | 37.6 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 3.88 [0.20, 74.00] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 3.75 [0.85, 16.64] | | < 1 | | 0% | 1 study (1/-) | 4.2 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 2.45 [0.53, 11.36] | | < 1 | | 0% | 1 study (1/-) | 12.6 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.24 [0.01, 7.16] | | < 1 | | 0% | 1 study (1/-) | 79.2 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 5.87 [0.33, 105.85] | | < 1 | | 0% | 1 study (1/-) | 11.8 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 3.88 [0.20, 74.00] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.42 [0.18, 0.97] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 0.48 [0.03, 7.71] | | < 1 | | 0% | 1 study (1/-) | 69.7 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 3.88 [0.20, 74.00] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 2.90 [0.14, 58.35] | | < 1 | | 0% | 1 study (1/-) | 24.6 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.64 [0.14, 2.88] | | < 1 | | 0% | 1 study (1/-) | 72.1 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.12 [0.01, 2.65] | | < 1 | | 0% | 1 study (1/-) | 90.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.70 [0.35, 8.29] | | < 1 | | 0% | 1 study (1/-) | 25.7 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.90 [0.91, 3.94] | | < 1 | | 0% | 1 study (1/-) | 4.3 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 2.11 [0.70, 6.39] | | < 1 | | 0% | 1 study (1/-) | 9.4 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.96 [0.09, 10.69] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |